Studying the body's response to infliximab injection for inflammatory bowel disease
Part of Bones, joints & muscles, Digestive system, Immune system & allergy, Skin clinical trials.
This study tests a medicine called infliximab, given as an injection under the skin, to see how the body processes it in people with inflammatory bowel disease (Crohn's disease or ulcerative colitis). It may help find the best dose for your condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Crohn's disease with a moderate to severe disease activity (score between 220 and 450 on a standard scale).
- Or you have ulcerative colitis with active disease (score between 6 and 12 on the Mayo scale).
- You have not been treated with a biologic medicine (like anti-TNF drugs) for your IBD before.
- You are not allergic to infliximab or any of its components, or to other similar proteins.
- You do not have HIV, hepatitis B, or hepatitis C (past hepatitis B that fully resolved may be okay).
- You have not had a recent or serious infection (like needing antibiotics within the last 2–4 weeks, or a serious infection within the last 6 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is looking at children and teenagers with Crohn's disease or ulcerative colitis who are starting a biologic medicine called infliximab. It aims to learn more about how this treatment works in young patients.
This trial is testing a new way to give infliximab, a treatment for moderate to severe Crohn's disease, as a shot under the skin. It's for people who haven't gotten better with other treatments or need strong medication right away.
This trial tests whether closely monitoring and adjusting infliximab (a biologic medicine) can help people hospitalized with a moderate-to-severe flare of Crohn's disease, ulcerative colitis, or unclassified inflammatory bowel disease who haven't gotten better with IV steroids. The goal is to improve treatment response and outcomes.
This study tracks how patients with Crohn's disease or ulcerative colitis respond to infliximab (a biologic medication) given as injections under the skin after an initial IV dose. Researchers want to understand which patients benefit most and for how long.
This study tests whether switching from an IV infliximab to a subcutaneous (under-the-skin) version is safe and works well for people with moderate to severe Crohn's disease. It's for people who have never used a biologic and need a new treatment option.
This trial tests a more precise way to start infliximab (a Crohn’s medicine) and adjust dosing based on how your body responds. It aims to better control Crohn’s inflammation early and keep it under control.
Hear when a new IBD - Inflammatory Bowel Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.